GSK Financials - Benzinga

GSK PLC

GSKNYSE

Trade with Public

Trade with Public

$49.17

-0.53-1.06%

마지막 업데이트: Sep 29, 10:30 AM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 배당금 비교 옵션 주식 보고서

GSK Financials

GSK (GSK) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals

GSK beats Q2 revenue and earnings estimates, launches a $2.52B cost-savings program, and updates its 2026 guidance.

Vandana Singh

PRO
GSK FY2031 Revenue expected to be more than $53.204B vs $45.690B Est

GSK (NYSE:GSK) FY2031 Revenue expected to be more than $53.204B vs $45.690B Est

Benzinga Newsdesk

PRO
GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.79 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.690B Est

GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.79 analyst estimate. Affirms FY2026 sales outlook from $44.754 billion to $44.754 billion vs $45.690 billion estimate.

Benzinga Newsdesk

PRO
GSK Q2 Adj. EPS $1.35 Beats $1.27 Estimate, Sales $11.280B Beat $10.790B Estimate

GSK (NYSE:GSK) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.27 by 6.3 percent. This is a 8.87 percent increase over earnings of $1.24 per share from the same period last

Benzinga Newsdesk

Tempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook amid strong AI & diagnostic demand.

Lekha Gupta

Earnings Scheduled For April 29, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved